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Terpenoids constitute the largest, most diverse group of natural products with 
numerous ones garnering commercial and medicinal interest. Most terpenoids are 
naturally produced in low amounts so their purification suffers from low yields and 
consumption of large amounts of natural resources. Hence, the extinction of the 
natural source becomes a real threat and the amount of isolated compound usually 
cannot cover market demand especially for medicinally important compounds like 
anticancer paclitaxel and antimalarial artemisinin. Also, synthesis of most terpenoids is 
problematic and expensive due to the complexity of their structures. Thus, the need for 
alternate methods of terpenoid production is a pressing issue. Among these methods is 
the microbial production of terpenoids, which has been researched in the last few 
decades. The objectives of the thesis by Ingy Abdallah are establishing the Gram-
positive bacterium Bacillus subtilis as a platform organism for terpenoid production by 
understanding and improving the biosynthetic routes of terpenoids including the core 
enzymes involved in the process such as terpene synthases. A B. subtilis strain 
overexpressing the terpenoid biosynthetic pathway was successfully engineered then 
used for the production of C30 carotenoids and the diterpene precursor of paclitaxel, 
taxadiene. This strain can serve as a cell factory for production of various terpenoids. In 
addition, the research in this thesis delved into the enzyme family of terpene synthases, 
which are essential for the formation of terpenoids. The focus was on understanding 
the structure-function relations of amorphadiene synthase, a key enzyme in artemisinin 
production, and improving its catalytic activity. 
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Nature provides a wealth of compounds with commercial and/or medicinal 
significance. Among these natural products, terpenoids are very famous. Terpenoids 
are considered one of the largest classes of natural products with vast structural and 
functional diversity. They are widespread amid various organisms where they are 
important for several vital functions. Numerous terpenoids are harvested from 
microbes and plants for countless applications ranging from food to cosmetics to 
pharmaceuticals or nutraceuticals. For example, carotenoids possessing antioxidant 
properties, volatile monoterpenes used as flavors and fragrances, anticancer paclitaxel 
and antimalarial artemisinin. 
In spite of the huge diversity in the chemical structures of terpenoids, they are all 
synthesized by consecutive condensation of two five-carbon precursors, isopentenyl 
pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP). These 
precursors are synthesized via two distinct pathways, the mevalonate (MVA) or the 2-
C-methyl-D-erythritol-4-phosphate (MEP) pathways. These building blocks are then
fused through different number of repeats to produce the backbones of all terpenoids.
The backbones are then cyclized and/or rearranged by terpene synthase enzymes to
produce the corresponding terpenoids. Terpene synthases are a class of enzymes that
are essential for the production of the desired terpenoids.
Most terpenoids are naturally produced in low concentrations so purification from 
their natural biological material suffers from low yields and consumption of large 
amounts of natural resources. This can lead to extinction of the original species and 
usually the amount of isolated compound cannot cover market demand especially for 
medicinally important compounds like paclitaxel and artemisinin. Also, organic 
synthesis of most terpenoids is problematic and costly due to the complexity of their 
structures. Hence, alternate methods for production of terpenoids have been 
researched in the last few decades. Among these methods is the microbial production 
of terpenoids. Microbial hosts such as Escherichia coli, Saccharomyces cerevisiae and 
Bacillus subtilis were studied for their ability to act as platform organisms for 
production of terpenoids. An understanding of the biosynthetic routes for production 
of terpenoids including the core enzymes involved in this process such as terpene 
synthases is crucial for engineering a host for terpenoid production, in addition, to the 
knowledge of the inherent metabolic pathways of the selected host. This allows for the 
transfer of all or parts of the terpenoid biosynthetic pathways to heterologous hosts in 
order to create a cell factory for production of important terpenoids.  
Chapter 1 is an overview of the biosynthesis of terpenoids, their different classes, the 
terpene synthases enzyme family and some examples of engineering microbial cell 
factories for terpenoid production. 
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The research in this thesis aims at metabolic engineering of a microbial host as a cell 
factory for terpenoid production. B. subtilis was chosen as the platform organism due 
to its successful use for industrial production of proteins, in addition to the fact that it 
is the highest isoprene (C5 terpenoid) producer among the well-known microorganism 
hosts. Moreover, the second part of this thesis focuses on studying the famous 
sesquiterpene synthase, amorphadiene synthase, which is responsible for production of 
the precursor of the antimalarial drug artemisinin. 
Engineering Bacillus subtilis as a cell factory for terpenoid production 
B. subtilis has been extensively used as a host for bulk industrial enzyme production. It
has high potential to act as a high-grade cell factory. B. subtilis possesses an inherent
MEP pathway producing high levels of isoprene. It has a wide metabolic potential, and
varied substrate range. It has higher growth rate compared to yeast. Moreover, B.
subtilis is listed by the Food and Drug Administration as generally regarded as safe
(GRAS) which is an advantage over E. coli. Recently, researchers started focusing on
engineering B. subtilis to produce valuable terpenoids in a manner similar to the
research performed on the yeast S. cerevisiae and E. coli but taking into account the
advantages of B. subtilis as a potentially better cell factory. In Chapter 2, we review the
inherent terpenoid biosynthetic pathways of B. subtilis along with the challenges facing
the engineering of B. subtilis for production of valuable terpenoids, major advances and
future directions for using B. subtilis as a cell factory.
Our efforts to engineer B. subtilis for terpenoid production start in Chapter 3 where we 
overexpress different enzymes involved in the MEP pathway to boost the production of 
the precursors IPP and DMAPP required for biosynthesis of terpenoids. We describe 
the systematic overexpression of the enzymes from the B. subtilis MEP pathway and we 
use the level of production of orange colored C30 carotenoids, which were previously 
successfully produced in B. subtilis, as a read out to evaluate the effect of such 
modulations on terpenoid production. We assembled the endogenous genes of B. 
subtilis encoding the MEP pathway enzymes one by one in a synthetic operon that is 
expressed from a plasmid. The operon was constructed to contain up to four genes 
based on their significance in previous literature reports. The successful expression of 
the enzymes from a plasmid based system was demonstrated. After that, the B. subtilis 
strains overexpressing different sets of enzymes of the MEP pathway were combined 
with a C30 carotenoid producing plasmid. The orange colored carotenoids, 4,4’-
diaponeurosporene and 4,4’-diapolycopene, were extracted from the different strains 
and quantified by HPLC. It was shown that each consecutive expression of an 
additional enzyme involved in the MEP pathway resulted in a higher amount of 
carotenoids detected. The two strains overexpressing four of the MEP pathway 
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enzymes showed the highest amount of carotenoid production compared to the other 
strains. The strain overexpressing ispC, ispE, ispG, and ispA showed slightly higher 
amount (10.65 mg/g dcw) compared to the strain overexpressing dxs, ispD, ispF, and 
ispH (9.03 mg/g dcw). Figure 1 shows the upper MEP pathway producing IPP and 
DMAPP and the lower pathway for conversion of these precursors to the terpenoid 
backbones, which in turn are transformed by the terpene synthases to the desired 
terpenoids. 
Figure 1. Biosynthesis of terpenoids in B. subtilis via the MEP pathway. 
Chapter 10 
240 
As a continuation of the research into the modulation of the MEP pathway of B. 
subtilis, in Chapter 4, we compare expression vectors with different origins of 
replication and promoters to choose the most stable expression system in B. subtilis. In 
addition, all the eight genes of the MEP pathway were combined in a single operon in a 
plasmid based expression system. The theta-replicating plasmid (pHCMC04G) was 
proven to be more structurally and segregationally stable compared to the rolling circle 
replication plasmid (pHB201) especially for large size operons containing three or 
more genes. Hence, the pHCMC04G vector with its xylose inducible promoter was 
used as the host of the operon containing the eight genes. RT-qPCR was used to prove 
that the transcripts are intact and all genes are expressed at the same level irrespective 
of their position in the operon. Finally, the amount of C30 carotenoids produced 
confirmed that the pHCMC04G plasmid is superior compared to pHB201. The B. 
subtilis strain overexpressing all eight genes of the MEP pathway (p04_SDFHCEGA) 
showed the highest carotenoid production (21 mg/g dcw) which is nearly twice the 
amount produced by the strains overexpressing only four genes. 
In Chapter 5, we make use of the best B. subtilis strain generated from the previous two 
chapters (p04_SDFHCEGA) to aim at the production of taxa-4,11-diene which is the 
precursor of the anticancer paclitaxel. In the effort towards engineering B. subtilis as a 
host for the production of paclitaxel, we expressed the plant-derived taxadiene synthase 
(TXS) enzyme, which is responsible for the conversion of the precursor geranylgeranyl 
pyrophosphate (GGPP) to taxa-4,11-diene. This is the first committed intermediate in 
paclitaxel biosynthesis. The txs gene was integrated into the genome of B. subtilis and 
the TXS enzyme was successfully expressed for the first time in B. subtilis. Additionally, 
genes encoding biosynthetic enzymes from the MEP pathway [dxs, ispD, ispF, ispH, 
ispC, ispE, ispG] and early terpenoid biosynthesis [ispA encoding IspA that performs 
the function of geranyl pyrophosphate synthase (GPPS) and farnesyl pyrophosphate 
synthase (FPPS), crtE encoding geranylgeranyl pyrophosphate synthase (GGPPS)] were 
cloned into B. subtilis and their effect on taxadiene production was evaluated. The over 
expression of the MEP pathway enzymes along with IspA and GGPPS caused 83-fold 
increase in the amount of taxadiene produced compared to the B. subtilis strain only 
expressing TXS and relying on the innate pathway of B. subtilis. The total amount of 
taxadiene produced by that strain was 17.2 mg/L which is higher than the amounts 
reported for E. coli and S. cerevisiae on shake flask fermentation level. 
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Study of terpene synthases with emphasis on amorphadiene synthase 
The participation of a terpene synthase is an indispensable prerequisite for the 
synthesis of terpenoids. Terpene synthases constitute a family of enzymes tasked with 
catalyzing the cyclization and/or rearrangement of the precursors geranyl 
pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl 
pyrophosphate (GGPP) to create the different classes of terpenoids. The mechanism of 
terpene synthases is complex where the diverse array of terpenoid structures depend on 
the orientation of the flexible substrate in their large active site. Terpene synthases are 
divided into different classes to produce the numerous terpenoids. We focus on the 
class of sesquiterpene synthases, which are responsible for converting the substrate FPP 
to more than 300 sesquiterpenes (C15). They are classified into transoid sesquiterpene 
synthases that catalyze the ionization of the (trans, trans)-substrate and cisoid ones 
which execute an initial double bond isomerization to create a (cis, trans)-intermediate 
carbocation. All sesquiterpene synthases possess a tri-nuclear metal cluster liganded by 
conserved metal ion binding motifs DDXXD and (N,D)DXX(S,T)XXXE that prompt 
the ionization of the pyrophosphate group of the substrate to initiate the catalytic 
mechanism. 
Among the most prominent sesquiterpene synthases is amorphadiene synthase (ADS). 
ADS catalyzes the cyclization of FPP to amorpha-4,11-diene, which is considered the 
first and rate limiting step in the synthesis of the antimalarial drug artemisinin. 
Artemisinin-based combination therapies (ACTs) are recommended as the first-line 
treatment of malaria by The World Health Organization (WHO). Also, artemisinin has 
recently been gaining attention for its possible chemotherapeutic effect in fighting 
cancers. Understanding the biosynthesis of artemisinin will help optimize its 
production and increase its availability at lower price. Hence, we focused on studying 
the enzyme amorphadiene synthase to gain better insight into the structure-function 
relations within the catalytic mechanism and to aim at improving its activity. 
Amorphadiene synthase is a cisoid sesquiterpene synthase. In spite of the numerous 
research into this enzyme, obtaining an X-ray crystal structure has not been successful. 
Thus, the structural basis of its catalytic mechanism is still unknown, as the molecular 
conformation of the enzyme has not been characterized. In Chapter 6, we created a 
reliable three-dimensional (3D) homology model representing the conformation of the 
ADS enzyme using Discovery Studio software. The model was produced using the 
crystal structure of α-bisabolol synthase, an enzyme with high sequence identity with 
ADS, as a template. Three magnesium ions representing the tri-nuclear metal cluster 
were positioned in the active site and confirmed by their chelation with the metal ion 
binding motifs. Subsequently, the substrate FPP was docked into the active site and the 
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different conformations produced were evaluated for their folding and interactions 
leading to the selection of one conformation as the best fit for the substrate in the active 
site . The 3D model was validated by assessing its stereochemical quality in addition to 
probing some of the active site residues through site-directed mutagenesis. The 
generated variants confirmed the validity of the ADS model. 
The generated ADS model was used in Chapter 7 to select active site residues for 
creating a mutability landscape of ADS. A mutant library of 257 variants encompassing 
the sixteen residues: R262, R440, Q518, H392, H448, L515, K449, V396, F525, Y519, 
W271, T296, T399, G400, G439 and D523 was produced. This mutant library was 
screened for catalytic activity and product profile to determine the residues involved in 
the mechanism of ADS and their respective roles. This screening proved that aromatic 
residues (W271, Y519 and F525) are essential for stabilization of the reactive 
carbocations in the active site. The basic histidines, 392 and 448, were excluded as the 
active site catalytic base while W271 proved to be a possible candidate for this function. 
The role of T399 in regioselective deprotonation was corroborated. Moreover, R262 
creates a region of high positive charge along with the magnesium ions in the active site 
to neutralize the negative charge of the released pyrophosphate preventing it from 
interfering with the reactive carbocations. R440 and K449 were excluded from this 
function. Also, the landscape helped select variants with improved catalytic activity 
compared to wild type ADS. Several variants having the same product profile as wild 
type ADS showed improved catalytic activity. The H448A variant displayed high 
improvement with almost four times increase in catalytic efficiency compared to wild 
type ADS. The double mutant T399S/H448A showed turnover rate (kcat) five folds 
higher than the wild type. Figure 2 summarizes the research in chapters 6 and 7 starting 
with creating the ADS model then generating the mutant library followed by screening 
the mutability landscape for product profile and catalytic activity. 
Finally, Chapter 8 focused on evaluating the impact of mutating a single active site 
residue on the promiscuity of amorphadiene synthase. The major product of ADS is 
amorpha-4,11-diene along with several minor products such as β-farnesene, γ-
humulene, α-bisabolol, amorpha-4,7-diene and amorpha-4-en-11(7)-ol. Using the ADS 
mutability landscape for product profile generated in Chapter 7, we identified variants 
that increase the production of one or more of these minor products at expense of the 
major amorpha-4,11-diene. Six plasticity residues were probed, namely V396, T399, 
G400, H448, L515 and D523. Mutation of residue L515 reduced product specificity 
unless conserved as isoleucine, valine or proline. Residue G400 must be conserved to 
maintain activity and product specificity. Replacing V396 with acidic residues impaired 
the regioselective deprotonation as well as substituting T399 with amino acids other 
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than serine. Also, the two variants, H448P and D523A, greatly diminished the product 
specificity of ADS by producing amorpha-4-en-7(11)-ol as the major product. 
Figure 2. Summary of the research in chapters 6 and 7. 
(A) The generated ADS 3D model. (B) The ADS mutant library consisting of 257 variants.
(C) GC chromatogram showing the product profile of wild type ADS. (D) Mutability landscape




Conclusions and future perspectives 
The overall aim of this thesis is to create a sustainable terpenoid cell factory. To achieve 
this goal, we focused on two main areas. The first part of the thesis researched the 
engineering of B. subtilis as a platform organism for terpenoid production. We started 
by modulating the inherent biosynthetic MEP pathway in B. subtilis required for 
production of the terpenoid precursors and we evaluated its effect on production of C30 
carotenoids. We successfully generated a strain stably overexpressing all eight genes of 
the MEP pathway from a plasmid based system in B. subtilis. That strain produced a 
high amount of C30 carotenoids. Moreover, the gene for the enzyme taxadiene synthase 
was incorporated in the genome of the B. subtilis strain overexpressing the full MEP 
pathway leading to the production of high levels of taxa-4,11-diene, the precursor of 
paclitaxel, superior to E. coli and S. cerevisiae. The second part of our work delved into 
the terpene synthase enzymes essential for synthesis of terpenoids. We focused on 
studying the enzyme amorphadiene synthase which is important due to its role in the 
synthesis of artemisinin. We successfully created a 3D model of the enzyme and used it 
to build a mutability landscape that helped understand the role of some active site 
residues in the mechanism of ADS and identify variants with improved activity 
compared to the wild type. 
In the future, the superior B. subtilis created in this research can be used as a cell factory 
for production of any number of terpenoids where the terpene synthase of the desired 
terpenoid can be introduced into its genome similar to our work with taxadiene 
synthase. In addition, further improvement to the production levels can be achieved by 
optimizing the growth medium and/or incorporating the mevalonate biosynthetic 
pathway to further boost the production of terpenoid precursors. Scaling up to large 
scale industrial fermenters along with further tuning of growth conditions should be 
performed to optimize the B. subtilis strain producing taxadiene. This cell factory can 
be used for industrial production of paclitaxel by combining it with the remaining 
enzymes in their biosynthetic pathway and optional chemical conversions. Based on 
the advantages of B. subtilis compared to other cell factories, this can provide a path for 
a more efficient approach for production of semisynthetic paclitaxel or artemisinin. 
Moreover, the ADS variant with improved catalytic activity can be cloned into any 
microbial host to achieve better production of amorpha-4,11-diene to what is known 
now using wild type ADS. This is the stepping stone for improving production of 
artemisinin. 


